Functionalization of rare noncoding variants as drivers of alzheimer's disease risk

Active Grant Awarded

Award ID
R01AG093119
Recipient
Awarding agency
Obligated
$845,617

Award facts

Assistance listing
93.866 Aging Research
Completion date 4% complete
Place of performance
San Francisco, CA 94158, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute on Aging awarded $845,617 to J.david Gladstone Institutes on September 9, 2026, under Grant R01AG093119 in the Aging Research program (CFDA 93.866). The award funds research titled "Functionalization of Rare Noncoding Variants as Drivers of Alzheimer's Disease Risk," which develops strategies for uncovering the genetic drivers of Alzheimer's disease that reside in noncoding portions of the genome. The project period ends May 31, 2031, and the work is performed in San Francisco, CA 94158, USA. The Aging Research program supports biomedical, social, and behavioral research on the aging process and its diseases, with particular emphasis on preventing and treating Alzheimer's disease and related dementias.

Description

Abstract
Alzheimer's disease (ad) manifests as an age-related progressive neurodegeneration with concomitant loss of cognitive function. As the most common neurodegenerative disease, ad plagues >55 million individuals worldwide and this number is expected to double by 2050. No therapies exist to prevent, stop, or cure the neurodegeneration associated with ad, marking ad as one of the greatest unmet clinical needs of our time. Twin studies demonstrate that ad is ~70% heritable, meaning that the majority of ad risk is encoded within our genomes. While studies of common genetic variants and familial forms of ad have uncovered key driver genes such as apoe, PSEN1/2, and APP, our current knowledge of ad genetics only explains ~11% of the genetic variation linked to ad risk. We postulate that much of the unexplained genetic predisposition to ad is accounted for by rare variants, and in particular by rare variants in the noncoding portion of the genome. Rare noncoding variants remain mostly unexplored because they are harder to analyze than coding variants, and to link to disease via statistical association tests than are common variants. Together, this illustrates the immediate need for development of new strategies capable of uncovering the missing genetic drivers of ad which largely reside within parts of the genome that have been challenging to interrogate. Yet, rare variants are particularly attractive targets for therapeutic development as they often have higher effect sizes than do common variants. Therefore, they point to genes or biological processes that, when targeted, could bring large therapeutic benefits. However, each individual harbors >10,000 noncoding rare variants, making the haystack very large and intractable with current genetics approaches which would require sequencing more than 8 million ad cases in order to capture just 80% of ad genetic predisposition (we currently have fewer than 100,000 sequenced cases). Here, we propose to develop novel machine learning models that can prioritize noncoding variants based on their predicted impact on cell-specific regulation of gene expression (aim 1). By applying these models to ad cases that should be enriched for rare variant drivers, we will trim the rare noncoding variant haystack from millions to thousands. We will then implement an in vitro functional assay, a massively parallel reporter assay (MPRA), to further prioritize variants based on their impact on gene expression in a variety of brain cells in culture (aim 2). Finally, we will test whether we can boost the statistical power of rare variant association testing by focusing on the subset of rare variants predicted to have a functional impact by our machine learning tools and MPRA assays (aim 3). In all, our work will put forward a novel strategy for uncovering large-effect-size rare variants driving ad risk and identify candidate genes behind many so far unexplained cases of familial or sporadic ad. This work will bring US closer to our long-term goal, which is to complete our understanding of genetic predisposition to ad and to inspire therapeutic strategies that target many patients and disease etiologies.

Quick answers

Who received award R01AG093119?

R01AG093119 was awarded to J.david Gladstone Institutes by National Institute on Aging (National Institutes of Health) on September 9, 2026.

How much is award R01AG093119 worth?

$845,617 has been obligated on R01AG093119.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award